Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%
Pharmaceutical stocks faced pressure after US President Trump unveiled a phased tariff plan for imported generic medicines.
This plan introduces steep duties on generic drugs after a two-year tariff-free window.
Indian drugmakers are reassessing supply chains and investment plans due to potential future impacts.
Companies without US manufacturing presence may face significantly altered economics.
The announcement shifts focus to encouraging domestic production within the United States.
Trump Plans 200% Tariff on Generic Drugs
- Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit? The Indian Express —
- Trump outlines plans for up to 200% tariffs on generic drug imports starting in 2028 Seeking Alpha —
- Trump Plans 100% Tariff on Generic Drugs From 2028 | Insight with Haslinda Amin 7/22/2026 ๐น Bloomberg — ยท 47min
- Trump drops tariff bombshell on generic drugs with 200% threat The Independent —
- India's pharma takes 'wait-and-watch' approach to tackle Trump's 200% tariff plan | What next? Mint —